Natixis Advisors L.P. Has $122.62 Million Position in Sanofi (NASDAQ:SNY)

Natixis Advisors L.P. cut its position in Sanofi (NASDAQ:SNY) by 2.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,465,762 shares of the company’s stock after selling 62,527 shares during the quarter. Natixis Advisors L.P. owned about 0.10% of Sanofi worth $122,622,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. McIlrath & Eck LLC grew its position in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after purchasing an additional 361 shares in the last quarter. Hexagon Capital Partners LLC boosted its stake in shares of Sanofi by 24.5% in the fourth quarter. Hexagon Capital Partners LLC now owns 4,993 shares of the company’s stock valued at $248,000 after buying an additional 984 shares during the period. Altrius Capital Management Inc grew its position in Sanofi by 1.7% during the fourth quarter. Altrius Capital Management Inc now owns 135,311 shares of the company’s stock worth $6,729,000 after buying an additional 2,318 shares in the last quarter. Transcend Capital Advisors LLC increased its stake in Sanofi by 5.7% during the 4th quarter. Transcend Capital Advisors LLC now owns 5,730 shares of the company’s stock worth $285,000 after acquiring an additional 307 shares during the period. Finally, Unique Wealth Strategies LLC acquired a new position in Sanofi in the 4th quarter valued at $577,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley assumed coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Price Performance

SNY stock traded down $0.77 during trading on Thursday, reaching $49.26. 3,995,711 shares of the company were exchanged, compared to its average volume of 2,040,065. The company has a 50-day moving average of $47.86 and a two-hundred day moving average of $48.26. The company has a market capitalization of $124.61 billion, a price-to-earnings ratio of 24.63, a P/E/G ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.93.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, equities analysts predict that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.